7:30 am Morning Registration & Coffee

8:20 am Chair’s Opening Remarks

Evaluating the LNP Landscape

8:30 am Panel Discussion: Setting the Context – Current & Potential Uses of LNPs


Kicking off the summit, hear from industry experts who can set the stage. Given the rapid expansion of the use of LNPs, let’s reset the context and evaluate where we are today.

  • What are the existing uses of LNPs?
  • Where do we see them moving into in the future?
  • What do we have left to face?

9:00 am Virtual Pro-Inflammatory Concerns Associated with LNPs


  • Exploring the mechanisms by which nanoparticles trigger an inflammatory response
  • PEG-associated inflammation – how your formulation impacts the response

9:30 am Analysing mRNA & LNP Lipid Quality for Better Genetic Medicines

  • Stephen Lock Senior Market Development Manager, Biopharma EMEAI, SCIEX


  • Understand the latest approaches to determine mRNA purity and integrity pre and post encapsulation
  • Discover why process-related lipid impurities are a concern in therapeutics and vaccines
  • Explore how to gain deeper structural insights into lipids and impurities with advanced LC-MS technology

10:00am | Speed Networking & Morning Coffee

Delving into On & Off-Target Delivery

11:15 am Biomolecular Oligonucleotide Assembles for Systemic Delivery of Therapeutic Nucleic Acids

  • Ken Howard Associate Professor, Aarhus University


  • Exploring alternative methods to deliver nucleic acids
  • Discussing advantages: the natural transport properties and ability to tune the PK with recombinant variants of albumin provides the perfect scaffold for biomolecular drug assemblies
  • Incorporation of nucleic acid oligonucleotide modules into the design allows
    multifunctionalisation and incorporation of therapeutics

11:45 am Virtual Navigating the IP Landscape for LNP Delivery Technology


  • Surveying the current IP and competitive landscape for LNP delivery technology
  • Considering approaches for licensing and strategic collaborations
  • Reviewing IP protection strategies for new innovations

12:15 pm GenVoy™ Lipid Nanoparticles: A Versatile Tool for Developing RNA Vaccines


  • Delving into successful development of an RNA-LNP: optimal RNA vector design, LNP delivery system and robust manufacturing process
  • Outlining a study where we demonstrate how an early vaccine development workflow can be accelerated from inception to early pre-clinical studies
  • Demonstrating how GenVoy-ILM™ together with the NanoAssemblr® Ignite™ can be used to optimize an RNA-LNP vaccine to illicit potent immune response against the target antigen

12:45pm | Networking Lunch

1:45 pm Fireside Chat: To the Liver & Beyond – Exploring Novel Delivery Areas


  • Modifying the payload to reach extrahepatic locations
  • Exploring novel formulation methods for improved delivery of LNPs
  • What challenges are faced?

2:15 pm Light Scattering Tools for Screening & Characterizing Lipid Nanoparticles


  • Choosing the optimum separation mechanisms for LNP analysis
  • Measurements of size- Choosing the optimum separation mechanisms for LNP analysis
  • Measurements of size, particle numbers, concentration and much, much more, particle numbers, concentration and much, much more

Maximising LNP Formulation Methods for Improved Processes

2:45 pm Alternative Systems for Mucosal Delivery of Nucleic Acids


  • Exploring barriers to mucosal (particularly oral) delivery of nucleic acids
  • Outlining an overview of drug delivery systems used for this purpose
  • Delving into extracellular vesicles for oral delivery of nucleic acids

3:15 pm Compliant Scalability of LNP Manufacture from Lab to 1 Billion Dose


  • A process engineering approach to scale up (not scale out)
  • End-to-end process considerations
  • PAT and the appropriate process analytics

3:30pm | Afternoon Break

4:00 pm Automated High-Throughput Screening of LNP Formulations

  • Ben Knappett Head of Science & Applications, Particle Works


  • Outlining the current challenges
  • Delving into the benefits of microfluidic technology
  • Employing automated mRNA-LNP formulation screening

4:15 pm Utilising Small-Angle Neutron Scattering (SANS) to Understand the Structure of LNPs

  • Zongyi Li Post-Doctoral Researcher , University of Manchester


  • What LNPs structure information can SANS tell?
  • Understanding LNP structure evolution during pH changes
  • Exploring a potential approach to link LNP formulation, structure, and function

4:45 pm Chair’s Closing Remarks & End of Day One